000126665 001__ 126665
000126665 005__ 20240228140840.0
000126665 0247_ $$2doi$$a10.1111/exd.12812
000126665 0247_ $$2pmid$$apmid:26186482
000126665 0247_ $$2ISSN$$a0906-6705
000126665 0247_ $$2ISSN$$a1600-0625
000126665 0247_ $$2altmetric$$aaltmetric:4291161
000126665 037__ $$aDKFZ-2017-02693
000126665 041__ $$aeng
000126665 082__ $$a610
000126665 1001_ $$aHao, Shuai$$b0
000126665 245__ $$amiR-137 inhibits proliferation of melanoma cells by targeting PAK2.
000126665 260__ $$aOxford$$bWiley-Blackwell$$c2015
000126665 3367_ $$2DRIVER$$aarticle
000126665 3367_ $$2DataCite$$aOutput Types/Journal article
000126665 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523949563_20742
000126665 3367_ $$2BibTeX$$aARTICLE
000126665 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126665 3367_ $$00$$2EndNote$$aJournal Article
000126665 520__ $$aMicroRNAs (miRNA) are key players in a variety of cancers including malignant melanoma. miR-137 has been reported to be a tumor suppressor in melanoma and several targets have been identified for this miRNA. We previously developed a novel proteomics technology, (35) S in vivo/vitro labelling analysis for dynamic proteomics (SiLAD). Because of its high sensitivity in analysing protein expression rates, SiLAD has the potential to unravel miRNA effects on mRNAs coding for proteins with long half-lives or high abundance. Using SiLAD, we discovered that miR-137 significantly downregulated the expression rate of p21-activated kinase 2 (PAK2) in melanoma cells. Bioinformatics analysis predicted PAK2 as a direct target of miR-137, which was confirmed by luciferase reporter assay and Western blot analysis. We found that overexpression of miR-137 inhibited the proliferation of melanoma cells, which could be phenocopied by knockdown of PAK2 using siRNAs. Furthermore, overexpression of PAK2 restored miR-137-mediated suppression of cell proliferation. These findings indicate that miR-137 could inhibit proliferation through targeting PAK2 in melanoma cells.
000126665 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000126665 588__ $$aDataset connected to CrossRef, PubMed,
000126665 650_7 $$2NLM Chemicals$$aMIRN137 microRNA, human
000126665 650_7 $$2NLM Chemicals$$aMicroRNAs
000126665 650_7 $$2NLM Chemicals$$aRNA, Neoplasm
000126665 650_7 $$2NLM Chemicals$$aRNA, Small Interfering
000126665 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aPAK2 protein, human
000126665 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$ap21-Activated Kinases
000126665 7001_ $$0P:(DE-HGF)0$$aLuo, Chonglin$$b1
000126665 7001_ $$0P:(DE-He78)ee782484657011f0081a1425afa47a3f$$aAbukiwan, Alia$$b2$$udkfz
000126665 7001_ $$aWang, Guangxia$$b3
000126665 7001_ $$aHe, Jinjun$$b4
000126665 7001_ $$aHuang, Lingyun$$b5
000126665 7001_ $$0P:(DE-HGF)0$$aWeber, Claudia E M$$b6
000126665 7001_ $$aLv, Na$$b7
000126665 7001_ $$aXiao, Xueyuan$$b8
000126665 7001_ $$00000-0002-3497-6904$$aEichmüller, Stefan B$$b9
000126665 7001_ $$aHe, Dacheng$$b10
000126665 773__ $$0PERI:(DE-600)2026228-0$$a10.1111/exd.12812$$gVol. 24, no. 12, p. 947 - 952$$n12$$p947 - 952$$tExperimental dermatology$$v24$$x0906-6705$$y2015
000126665 909CO $$ooai:inrepo02.dkfz.de:126665$$pVDB
000126665 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126665 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ee782484657011f0081a1425afa47a3f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000126665 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126665 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-3497-6904$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000126665 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000126665 9141_ $$y2015
000126665 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126665 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126665 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126665 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126665 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXP DERMATOL : 2015
000126665 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126665 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126665 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126665 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126665 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126665 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126665 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126665 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126665 9201_ $$0I:(DE-He78)G183-20160331$$kG183$$lPräklinische T-Zellforschung$$x0
000126665 980__ $$ajournal
000126665 980__ $$aVDB
000126665 980__ $$aI:(DE-He78)G183-20160331
000126665 980__ $$aUNRESTRICTED